Over the past decade, there has been a rapid expansion in the use of three-dimensional (3D) cell culture models, including organoids, across medical research, precision medicine, disease modeling, and drug discovery. These advanced cell culture systems are becoming valuable tools in preclinical research given their capacity to more accurately replicate the structural and functional characteristics of real human tissues, overcoming many of the limitations of traditional two-dimensional (2D) cell culture models.
Importantly, the U.S. Food and Drug Administration (FDA) roadmap to reduce reliance on animal testing emphasizes the need for validated new approach methodologies (NAMs). Organoids and other 3D models are a key factor of this strategy, as they offer physiological insights that can enhance the translational value of research while reducing the need for animal testing.
In alignment with these FDA priorities, Agilent has developed a broad range of assay workflows, integrating powerful and unique analysis platforms with organoids and other 3D models in mind. In this issue of TekTalk, we highlight several of these innovations, including the Agilent Seahorse XF Flex analyzer and Agilent Seahorse XF Flex organoid microplates which‒together‒enable comprehensive metabolic profiling of organoids. We also feature the Agilent xCELLigence RTCA eSight, which combines label free impedance measurements with live-cell imaging to support real time monitoring of organoid health, morphology, and behavior.
To complement these functional analyses, we highlight imaging strategies tailored for organoids and 3D models, which pose challenges due to greater thickness and optical complexity. The Agilent BioTek Cytation systems with Gen5 software meet these challenges by enabling straightforward low magnification screening and characterization of 3D samples alongside high resolution imaging that delivers clearer optical sectioning and detailed insights into cell model function and treatment response.
Additionally, plate reader–based biochemical assays, including ELISAs, provide robust and scalable orthogonal characterization of 3D systems. Agilent BioTek plate readers offer industry leading sensitivity and flexible detection modes, supporting high performance biochemical and immunoassay workflows that seamlessly complement imaging and real time analyses.
This application note describes the use of the Agilent Seahorse XF Flex organoid workflow for the metabolic profiling of cancer organoids using the Agilent Seahorse XF Flex analyzer and Agilent Seahorse XF Flex organoid microplate. The workflow was evaluated by examining the impact of metformin on mitochondrial function in cancer cell-derived organoids. This approach enables screening and characterization of drugs targeting mitochondrial function in 3D culture models such as cancer organoids.
We detail a high-throughput method for evaluating TGF-β/SMAD signaling in an A549 3D tumor model. Using confocal imaging on the Agilent BioTek Cytation C10, the study simultaneously quantifies biochemical markers, nuclear translocation of p-SMAD2/3 and SMAD4, and phenotypic EMT responses. A direct correlation between the magnitude of nuclear SMAD4 signal and the extent of cell migration from the spheroid core can be seen. This workflow shows how to effectively link intracellular signaling to morphological changes within a complex 3D multicellular model.
Different 3D systems such as spheroids, organoids, and scaffold-based cultures capture distinct aspects of tissue physiology, so defining the biological question and analytical endpoint is essential before selecting a model. Key considerations include:
Many organoid systems use ECM gels or coatings. For reliable, reproducible analysis, focus on the following high-impact practices:
Staining 3D cultures requires strategies that address limited diffusion, dense ECM, and fragile sample structure. The following high impact practices help ensure consistent, high quality labeling.
The Agilent Seahorse XF Flex enables the real-time measurement of cellular bioenergetics across diverse 3D study models, including organoids and tissue materials. In addition, the Agilent Seahorse XF Flex organoid microplate is optimized for matrix-embedded organoid culture, allowing long-term growth, high-resolution imaging, and comprehensive metabolic profiling within the same well. Together, they allow high resolution, functional metabolic profiling of organoids and other 3D models, enhancing translational relevance in disease research and drug screening.


Master complex 3D biology with the advanced optical sectioning capabilities of the Cytation C10 confocal imaging reader. The combination of automated confocal microscopy with multimode detection allows this system to capture deep Z-stacks to quantify nuclear translocation within thick 3D models while simultaneously measuring biochemical outputs. Experience the versatility needed to correlate subtle intracellular behavior with phenotypic outcomes in a single high-throughput workflow.
Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems use noninvasive biosensor technology to provide continuous, quantitative monitoring of cell health and behavior—ideal for environmental and water quality applications. This platform enables real-time assessment of processes such as chemical- and contaminant-induced cytotoxicity, with minimal hands-on effort. By delivering highly sensitive kinetic data, xCELLigence RTCA surpasses traditional endpoint assays, offering deeper insights into dynamic cellular responses to pollutants and pathogens.

A Z-stack and 3D rendering of an intestinal organoid model imaged with the spinning disk confocal optics of a Cytation C10. Caco-2 cells seeded and allowed to form a tube in the Mimetas OrganoPlate.

In alignment with FDA’s priority focused on new approach methodologies (NAMs), Agilent developed an assay workflow to interrogate energy metabolism and assess mitochondrial function in organoid cultures using the XF Flex organoid microplate and the XF Flex analyzer. This workflow empowers physiologically relevant discoveries in a wide range of biomedical research areas.
In this webinar, you will learn:
SOT 65th Annual Meeting and ToxExpo
March 22-25, 2026 | San Diego, CA
April 17-22, 2026 | San Diego, CA
xCELLigence Cancer & Immunotherapy Symposium
April 18, 2026 | San Diego, CA